Indication
Post-ET MF
1 clinical trial
1 product
Clinical trial
A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MyelofibrosisStatus: Active (not recruiting), Estimated PCD: 2024-04-01
Product
INCB018424/CC-4047